Item 7.01 Regulation FD Disclosure.

On January 11, 2022, Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos Therapeutics, Inc. (the "Company") presented at the 40th Annual J.P. Morgan Healthcare Conference (the "Conference"). The slides presented by Dr. Detheux at the Conference are furnished with this report as Exhibit 99.1, which is incorporated herein by reference.

The information in this Item 7.01 is furnished pursuant to Item 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01 Financial Statements and Exhibits.



Exhibit No. Description
99.1          iTeos Therapeutics, Inc. Presentation at the 40th Annual J.P.
            Morgan Healthcare Conference dated January 11, 2022
104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses